Mina Guirgis , Simon Keelan , Philip McEntee , Margaret Han , Paul Moroz
{"title":"下消化道肿瘤细胞减灭术后的静脉血栓栓塞事件","authors":"Mina Guirgis , Simon Keelan , Philip McEntee , Margaret Han , Paul Moroz","doi":"10.1016/j.sipas.2024.100257","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) represent a high-risk for venous thromboembolism (VTE) due to malignancy, prolonged surgery and immobility. We investigated the incidence of and risk factors for VTE following CRS/IPC.</p></div><div><h3>Materials and methods</h3><p>Data was analysed on 130 CRS/IPC performed over a 6-year period at a single centre, the Western Australian Peritonectomy Service (WAPS), on lower gastrointestinal neoplasia: pseudomyxoma peritoneii (PMP), colorectal cancer (CRC) and appendix cancer (AC). Data was analysed by univariate and multivariate logistic regression to identify risk factors for VTE.</p></div><div><h3>Results</h3><p>31 patients (24 %) experienced a VTE. The percentages of VTE among patients with PMP (<em>n</em> = 50), CRC (<em>n</em> = 53) and AC (<em>n</em> = 27) were 36 %, 17 % and 15 % respectively. 60 % of these cases were asymptomatic. The odds of VTE were higher for PMP patients than in patients with a other histopathology (OR=2.9, <em>p</em> = 0.01). Other significant risk factors for VTE on univariate analysis were PCI (OR=1.07, <em>p</em> = 0.001), pelvic dissection (OR=5.52, <em>p</em> = 0.001) and operation time (OR=1.36, <em>p</em> = 0.001).</p></div><div><h3>Conclusion</h3><p>This study demonstrates high rates of VTE in patients undergoing CRS/IPC. Patients with PMP have a three-fold higher risk of VTE compared to other malignancies (CRC+AC). As most VTE cases were asymptomatic, aggressive early investigation and intervention is indicated for patients undergoing CRS/IPC.</p></div>","PeriodicalId":74890,"journal":{"name":"Surgery in practice and science","volume":"18 ","pages":"Article 100257"},"PeriodicalIF":0.6000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266626202400024X/pdfft?md5=32beccafb0810696394fb376ba433f7a&pid=1-s2.0-S266626202400024X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Venous thromboembolic events following cytoreductive surgery for lower gastrointestinal neoplasia\",\"authors\":\"Mina Guirgis , Simon Keelan , Philip McEntee , Margaret Han , Paul Moroz\",\"doi\":\"10.1016/j.sipas.2024.100257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) represent a high-risk for venous thromboembolism (VTE) due to malignancy, prolonged surgery and immobility. We investigated the incidence of and risk factors for VTE following CRS/IPC.</p></div><div><h3>Materials and methods</h3><p>Data was analysed on 130 CRS/IPC performed over a 6-year period at a single centre, the Western Australian Peritonectomy Service (WAPS), on lower gastrointestinal neoplasia: pseudomyxoma peritoneii (PMP), colorectal cancer (CRC) and appendix cancer (AC). Data was analysed by univariate and multivariate logistic regression to identify risk factors for VTE.</p></div><div><h3>Results</h3><p>31 patients (24 %) experienced a VTE. The percentages of VTE among patients with PMP (<em>n</em> = 50), CRC (<em>n</em> = 53) and AC (<em>n</em> = 27) were 36 %, 17 % and 15 % respectively. 60 % of these cases were asymptomatic. The odds of VTE were higher for PMP patients than in patients with a other histopathology (OR=2.9, <em>p</em> = 0.01). Other significant risk factors for VTE on univariate analysis were PCI (OR=1.07, <em>p</em> = 0.001), pelvic dissection (OR=5.52, <em>p</em> = 0.001) and operation time (OR=1.36, <em>p</em> = 0.001).</p></div><div><h3>Conclusion</h3><p>This study demonstrates high rates of VTE in patients undergoing CRS/IPC. Patients with PMP have a three-fold higher risk of VTE compared to other malignancies (CRC+AC). As most VTE cases were asymptomatic, aggressive early investigation and intervention is indicated for patients undergoing CRS/IPC.</p></div>\",\"PeriodicalId\":74890,\"journal\":{\"name\":\"Surgery in practice and science\",\"volume\":\"18 \",\"pages\":\"Article 100257\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S266626202400024X/pdfft?md5=32beccafb0810696394fb376ba433f7a&pid=1-s2.0-S266626202400024X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgery in practice and science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266626202400024X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery in practice and science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266626202400024X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Venous thromboembolic events following cytoreductive surgery for lower gastrointestinal neoplasia
Introduction
Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) represent a high-risk for venous thromboembolism (VTE) due to malignancy, prolonged surgery and immobility. We investigated the incidence of and risk factors for VTE following CRS/IPC.
Materials and methods
Data was analysed on 130 CRS/IPC performed over a 6-year period at a single centre, the Western Australian Peritonectomy Service (WAPS), on lower gastrointestinal neoplasia: pseudomyxoma peritoneii (PMP), colorectal cancer (CRC) and appendix cancer (AC). Data was analysed by univariate and multivariate logistic regression to identify risk factors for VTE.
Results
31 patients (24 %) experienced a VTE. The percentages of VTE among patients with PMP (n = 50), CRC (n = 53) and AC (n = 27) were 36 %, 17 % and 15 % respectively. 60 % of these cases were asymptomatic. The odds of VTE were higher for PMP patients than in patients with a other histopathology (OR=2.9, p = 0.01). Other significant risk factors for VTE on univariate analysis were PCI (OR=1.07, p = 0.001), pelvic dissection (OR=5.52, p = 0.001) and operation time (OR=1.36, p = 0.001).
Conclusion
This study demonstrates high rates of VTE in patients undergoing CRS/IPC. Patients with PMP have a three-fold higher risk of VTE compared to other malignancies (CRC+AC). As most VTE cases were asymptomatic, aggressive early investigation and intervention is indicated for patients undergoing CRS/IPC.